PARP1 and cancer: Expression of mutp53-R273H in cancer cells also enhances their sensitivity to a combined treatment with a TopBP1-BRCT7/8 inhibitor and PARP or ATR (Ataxia Telangiectasia and Rad3-related protein) inhibitors.